Furthermore, defects caused by FUS or TDP-43 mutations have recently suggested to be regulated by HDAC6 inhibition [77, 78], indicating that HDAC6 may be a valuable target for ALS treatment. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.